Crohn’s disease: is a chronic inflammatory disease with a progressive and devastating course. Eventually, inflammation progresses to disease-related complications of intestinal damage, such as strictures, fistulas and abscesses, and the need for surgical resection. Traditional “upstaging”, i.e., sequential administration of corticosteroids and immunosuppressants, is an incremental treatment approach that does not stop disease progression, and repeated administration of corticosteroids over multiple courses is a significant risk factor for serious adverse events. Although the immunosuppressive agents azathioprine, 6-mercaptopurine, and methotrexate are alternatives to corticosteroid therapy, these agents are not efficient in inducing mucosal healing or stopping disease progression. Oncology: Necrosis factor antagonists can induce and maintain mucosal healing, reduce surgery and hospitalization rates, and increase the likelihood of preventing intestinal injury with long-term use of the drug, or In patients at higher risk of disease progression, combination therapy with immunosuppressive agents and tumor necrosis factor antagonists may be the best option to achieve optimal disease regression. Therefore, effective interventions should be initiated in Crohn’s patients before irreversible intestinal injury occurs.